% | $
Quotes you view appear here for quick access.

Neostem, Inc. Message Board

  • hwmccusker hwmccusker Jan 16, 2013 9:02 AM Flag

    New contract for PCT

    It is good start to the New Year. PCT’s services will include the transfer and qualification of Adaptimmune’s manufacturing process for its NYESO-1c259-T cell therapy product candidate. Adaptimmune develops products containing unique engineered T cell receptors for the treatment of cancer and infectious diseases. NBS closed at $0.63 and this event should add $0.01 to $0.03 to the share price.

    Sentiment: Strong Buy

2.91-0.1400(-4.59%)Apr 24 4:00 PMEDT